Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 54

Cited In for PubMed (Select 19726078)

1.

Clinical relevance of clopidogrel-proton pump inhibitors interaction.

Bouziana SD, Tziomalos K.

World J Gastrointest Pharmacol Ther. 2015 May 6;6(2):17-21. doi: 10.4292/wjgpt.v6.i2.17. Review.

2.

Treatment and prevention of gastrointestinal bleeding in patients receiving antiplatelet therapy.

Yasuda H, Matsuo Y, Sato Y, Ozawa S, Ishigooka S, Yamashita M, Yamamoto H, Itoh F.

World J Crit Care Med. 2015 Feb 4;4(1):40-6. doi: 10.5492/wjccm.v4.i1.40. eCollection 2015 Feb 4. Review.

3.

Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.

Dobesh PP, Oestreich JH.

Pharmacotherapy. 2014 Oct;34(10):1077-90. doi: 10.1002/phar.1477. Epub 2014 Aug 28.

4.

Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.

Depta JP, Lenzini PA, Lanfear DE, Wang TY, Spertus JA, Bach RG, Cresci S.

Pharmacogenomics J. 2015 Feb;15(1):20-5. doi: 10.1038/tpj.2014.28. Epub 2014 Jul 8.

PMID:
25001880
5.

Proton Pump Inhibitor use in Hospitalized Patients: Is Overutilization Becoming a Problem?

Durand C, Willett KC, Desilets AR.

Clin Med Insights Gastroenterol. 2012 Oct 15;5:65-76. doi: 10.4137/CGast.S9588. eCollection 2012. Review.

6.

Prognosis of concomitant users of clopidogrel and proton-pump inhibitors in a high-risk population for upper gastrointestinal bleeding.

Wang Q, Ljung R, Lagergren J, Lu Y.

BMC Pharmacol Toxicol. 2014 Apr 15;15:22. doi: 10.1186/2050-6511-15-22.

7.

Increased risk for developing major adverse cardiovascular events in stented Chinese patients treated with dual antiplatelet therapy after concomitant use of the proton pump inhibitor.

Zou JJ, Chen SL, Tan J, Lin L, Zhao YY, Xu HM, Lin S, Zhang J, Fan HW, Xie HG.

PLoS One. 2014 Jan 8;9(1):e84985. doi: 10.1371/journal.pone.0084985. eCollection 2014.

8.

Lifestyle factors among proton pump inhibitor users and nonusers: a cross-sectional study in a population-based setting.

Hvid-Jensen F, Nielsen RB, Pedersen L, Funch-Jensen P, Drewes AM, Larsen FB, Thomsen RW.

Clin Epidemiol. 2013 Dec 4;5:493-9. doi: 10.2147/CLEP.S49354. eCollection 2013.

9.

The use of H2 antagonists in treating and preventing NSAID-induced mucosal damage.

Tuskey A, Peura D.

Arthritis Res Ther. 2013;15 Suppl 3:S6. doi: 10.1186/ar4178. Epub 2013 Jul 24. Review.

10.

Antiplatelet drug interactions with proton pump inhibitors.

Scott SA, Owusu Obeng A, Hulot JS.

Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):175-89. doi: 10.1517/17425255.2014.856883. Epub 2013 Nov 9. Review.

11.

Pharmacogenetic testing: Current Evidence of Clinical Utility.

Moaddeb J, Haga SB.

Ther Adv Drug Saf. 2013 Aug 1;4(4):155-169.

12.

Esomeprazole and aspirin fixed combination for the prevention of cardiovascular events.

Sylvester KW, Cheng JW, Mehra MR.

Vasc Health Risk Manag. 2013;9:245-54. doi: 10.2147/VHRM.S44265. Epub 2013 May 16. Review.

13.

Platelet function testing to predict hyporesponsiveness to clopidogrel in patients with chest pain seen in the emergency department.

Sharma RK, Erickson SW, Sharma R, Voelker DJ, Reddy HK, Dod H, Marsh JD.

Vasc Health Risk Manag. 2013;9:187-93. doi: 10.2147/VHRM.S43909. Epub 2013 May 1.

14.

Current perspectives in NSAID-induced gastropathy.

Sinha M, Gautam L, Shukla PK, Kaur P, Sharma S, Singh TP.

Mediators Inflamm. 2013;2013:258209. doi: 10.1155/2013/258209. Epub 2013 Mar 12. Review.

15.

Impact of proton pump inhibitor therapy on the efficacy of clopidogrel in the CAPRIE and CREDO trials.

Dunn SP, Steinhubl SR, Bauer D, Charnigo RJ, Berger PB, Topol EJ.

J Am Heart Assoc. 2013 Jan 15;2(1):e004564. doi: 10.1161/JAHA.112.004564.

16.

Antiplatelet agents and proton pump inhibitors - personalizing treatment.

Lin E, Padmanabhan R, Moonis M.

Pharmgenomics Pers Med. 2010;3:101-9. Epub 2010 Jun 28.

17.

Impact of genetic polymorphisms on clinical response to antithrombotics.

Lanham KJ, Oestreich JH, Dunn SP, Steinhubl SR.

Pharmgenomics Pers Med. 2010;3:87-99. Epub 2010 Jun 18.

18.

Determinants to optimize response to clopidogrel in acute coronary syndrome.

Giusti B, Gori AM, Marcucci R, Saracini C, Vestrini A, Abbate R.

Pharmgenomics Pers Med. 2010;3:33-50. Epub 2010 Apr 8.

19.

What is the optimum prophylaxis against gastrointestinal haemorrhage for patients undergoing adult cardiac surgery: histamine receptor antagonists, or proton-pump inhibitors?

Patel AJ, Som R.

Interact Cardiovasc Thorac Surg. 2013 Mar;16(3):356-60. doi: 10.1093/icvts/ivs483. Epub 2012 Dec 2. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk